Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Long non-coding RNA landscape of patients biopsies from advanced Triple Negative Breast Cancer

ABSTRACT: The response to specific treatments relies on precise biomarkers, thereby avoiding undesirable toxicities and diminishing the cost. Due to the lack of treatment options in triple-negative breast cancer, it is crucial to search biomarkers with reasonable specificity and sensibility to recognize clusters of patients who could benefit from the cutting-edge oncologist treatments available nowadays. Microarrays were used to detail the global gene expression program to stratified TNBC patients according to TNBCtype software developed by Vanderbilt University and then identified lncRNAs expressed differentially through the TNBC subtypes.

ORGANISM(S): Homo sapiens

PROVIDER: GSE176128 | GEO | 2021/06/04

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data for Vanderbilt triple-negative breast cancer subtype classification

Project description:This study developed a triple-negative breast cancer (TNBC) surrogate subtype classification that represents TNBC subtypes based on the Vanderbilt subtype classification The web-based subtyping tool TNBCtype was used to classify the TNBC cohort into Vanderbilt subtypes

2023-03-04 | GSE226289 | GEO

Project description:Recurrence biomarkers of TNBC

| PRJNA750756 | ENA

Novel transcripts associated with lymph node metastasis in triple negative breast cancer [validation cohort]

Project description:Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype with the worst prognosis. It is characterised by the absence of hormone receptors for estrogen, progesterone, and human epidermal growth factor 2, and as a consequence there are no targeted endocrine treatments available. TNBC patients are more likely to develop metastases and disease relapse than patients with other breast cancer subtypes. The identification of biomarkers that can be used to predict which patient is likely to develop metastatic disease remains a priority since this is the major cause of cancer-related death in these women.

2015-12-02 | GSE61724 | GEO

Novel transcripts associated with lymph node metastasis in triple negative breast cancer [discovery cohort]

2015-12-02 | GSE61723 | GEO

microRNA expression profile in human Triple-Negative Breast Cancer stem cells

Project description:We reported the distinc expression pattern of TNBC-CSC-related microRNAs, which might be potential biomarkers and targeted therapy for TNBC.

2020-04-13 | GSE97765 | GEO

snRNA-seq of Lepr-cre; Tomato inWAT at different white-browning treatments

Project description:As obesity has becoming an urged issue nowadays, delineation of the mechanisms of WAT tissue white-browning and beige adipose origin are of important topic. By the use of snRNA-seq, we can outline LepR cells play important role in the white-browning process and investigate the mechanisms participate at different white-browning treatments.

2022-11-06 | GSE216925 | GEO

Proteomics and peptidomics of breast cancer subtypes

Project description:In our study, we applied high-throughput mass spectrometry, bioinformatic, and machine learning approaches to investigate the proteome, including noncoding RNA (ncRNA)–derived micropeptides, of different breast cancer subtypes. In total, 19 tumor and 18 paired nontumor samples were used to obtain the proteome and peptidome. Among these, 5 samples were classified as LABC (plus 5 paired nontumor samples), 4 as LBBC (HER2−) (plus 4 paired nontumor samples), 4 as HER2+ breast cancer (plus 3 paired nontumor samples), and 6 as TNBC (plus 6 paired nontumor samples). We identified that each subtype depends on different protein expression patterns to sustain its malignancy,and also alterations in pathways and processes that can be associated with each subtype and its biological and clinical behaviors. Regarding subtype biomarkers, our panels achieved performances with at least 75% of sensibility and 92% of specificity. In the validation cohort, the panels obtained acceptable to outstanding performances (AUC = 0.740 to 1.00). We identified 58 peptides expressed on breast tissue, including 27 differentially expressed MPs in tumor compared with nontumor samples and MPs exhibiting tumor or subtype specificity. These peptides presented physicochemical features compatible with the canonical proteome and were predicted to influence the tumor immune environment and participate in cell communication, metabolism, and signaling processes. In addition, some MPs presented potential as anticancer, antiinflammatory, and antiangiogenic molecules.

2024-11-12 | PXD057759 | Pride

Transcriptome profiling of tumors from Kenyan triple negative breast cancer (TNBC) patients.

Project description:Triple negative breast cancer is an aggressive phenotypic breast cancer characterized by ER negative, PR negative and Her2 negative immunohistochemistry status. We embarked on a study to explore the transcriptome of Kenyan TNBC patients and identify potential biomarkers specific to Kenyan population. The transcriptome sequencing of tumors from Kenyan TNBC patients and comparisons with African American and Caucasian TNBC transcriptomes revealed several interesting targets and dysregulated pathways.

2021-04-28 | GSE142258 | GEO

Impairment of autophagic flux by combined EGFR and ROCK inhibition leads to triple-negative breast cancer cell death

Project description:Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with very limited therapeutic options. We have recently shown that the combined inhibition of EGFR and ROCK in TNBC cells results in cell cycle arrest and ultimately cell death. However, the underlying mechanisms by which co-inhibition of EGFR and ROCK induces cell death remain unclear. To investigate the synergistic effect of the combination treatment on TNBC cells, in the present study we applied a mass spectrometry-based proteomic approach to identify proteins altered upon single and combination treatments.

2019-12-04 | PXD013821 | Pride

Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer

Project description:Breast cancer is the most common malignancy that develops in women, responsible for the highest cancer-associated death rates. Triple negative breast cancers (TNBC) represent an important subtype that have an aggressive clinical phenotype, are associated with a higher likelihood of metastasis and are not responsive to current targeted therapies. miRNAs have emerged as an attractive candidate for molecular biomarkers and treatment targets in breast cancer, but their role in the progression of TNBC remains largely unexplored. This study has investigated miRNA expression profiles in 31 primary TNBC cases and in 13 lymph node metastases compared with 23 matched normal breast tissues to determine miRNAs associated with the initiation of this disease subtype and those associated with its metastasis. 71 miRNAs were differentially expressed in TNBC, the majority of which have previously been associated with breast cancer, including members of the miR-200 family and the miR-17-92 oncogenic cluster, suggesting that miRNAs involved in the initiation of TNBC are not subtype specific. However, the repertoire of miRNAs expressed in lymph node negative and lymph node positive TNBCs were largely distinct from one another. In particular, miRNA profiles associated with lymph node negative disease tended to be up-regulated, while those associated with lymph node positive disease were down-regulated and largely overlapped with the profiles of their matched lymph node metastases. miRNA expression profiles were examined in 31 primary TNBC cases and in 13 lymph node metastases compared with 23 matched normal breast tissues

2014-11-24 | E-GEOD-38167 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data